A company checkup follows resources through the whole system公司体检要追踪资源如何穿过整个系统
Company financial analysis asks which operations produce profit, how much capital they occupy, whether earnings become usable cash, what claims debt and leases place on cash, how resources are allocated, and what remains per share. Consolidated totals are the starting pulse, not the diagnosis. Split mature operations from expansion cohorts, reconcile them to the group, and separate facts, calculations, assumptions, judgments, and missing evidence. The output is a financial condition report, not a valuation verdict.
公司财务分析要回答六个相互连接的问题：哪些业务创造利润，需要占用多少资本，报告利润能否转成可支配现金，债务与租赁对现金提出什么请求，分部与总部如何配置资源，最终每股承接到什么结果。合并总数只是最初的“脉搏”，不是诊断结论。应把成熟业务与扩张批次拆开，再勾回集团总数，并分别标记披露事实、计算、假设、判断与缺失证据。最终产物是一份有优先级的财务状况报告，而不是估值或交易结论。
Intake chart: CedarArc Regional Diagnostics接诊表：CedarArc 区域诊断网络
CedarArc Regional Diagnostics is a fictional laboratory network, not a real company or security. It operates eight mature labs and opened four sites in FY2026. Amounts are illustrative USD millions except per-share data and site counts; both fiscal years are twelve months ended 31 December. The case uses segment profit before unallocated corporate costs, while real filings may define segment measures differently.
CedarArc Regional Diagnostics 是为本教程虚构的区域诊断实验室网络，并非真实公司或证券。公司拥有八家成熟实验室，并在 FY2026 新开四个站点。除每股数据与站点数外，全部金额均为虚构的百万美元；FY2025 与 FY2026 都是截至 12 月 31 日的十二个月期间。案例采用“未分摊总部费用前分部利润”这一统一口径，真实申报文件可能采用不同的分部计量方法。
| Company vital sign | FY2025 | FY2026 | First triage question |
|---|---|---|---|
| Revenue | 150.0 | 192.0 | Which site cohort produced the growth? |
| Operating profit | 20.0 | 14.4 | Where did margin compress? |
| Net income attributable to ordinary holders | 12.0 | 8.4 | What changed below operating profit? |
| Operating cash flow | 25.0 | 38.0 | Is the cash repeatable and usable? |
| Capital expenditure | 12.0 | 45.0 | Maintenance or expansion? |
| Trade receivables, closing | 24.0 | 40.0 | Are payers taking longer? |
| Bank debt / lease liabilities, closing | 45.0 / 28.0 | 70.0 / 55.0 | What claims mature next? |
| Basic weighted-average shares | 50.0 million | 52.0 million | Did company growth reach each share? |
| 公司生命体征 | FY2025 | FY2026 | 首先分诊的问题 |
|---|---|---|---|
| 收入 | 150.0 | 192.0 | 增长由哪一批站点产生？ |
| 营业利润 | 20.0 | 14.4 | 利润率在哪里被压缩？ |
| 归属于普通股股东的净利润 | 12.0 | 8.4 | 营业利润以下发生了什么？ |
| 经营现金流 | 25.0 | 38.0 | 现金能否重复、能否动用？ |
| 资本开支 | 12.0 | 45.0 | 用于维持还是扩张？ |
| 期末贸易应收款 | 24.0 | 40.0 | 付款方是否变慢？ |
| 期末银行债务／租赁负债 | 45.0／28.0 | 70.0／55.0 | 近期有哪些到期请求？ |
| 基本加权平均股数 | 5,000 万股 | 5,200 万股 | 公司增长是否传到每股？ |
Case figures are stipulated facts. Formulas derived from them are calculations. Conditions not disclosed are assumptions. Explanations are judgments. Unavailable aging, covenants, and cohort data remain missing evidence—not blanks to fill with confidence.
贯穿全文的证据标签案例直接给出的数字属于“设定事实”，由数字推导的公式属于“计算”，披露未提供的条件属于“假设”，对原因的解释属于“判断”。无法获得的账龄、契约和站点批次数据，应保留为“缺失证据”，不能靠提高语气确定性来补空。
Examination room 1: locate the profit engine检查室一：定位盈利引擎
The consolidated picture says revenue rose 28.0%: (192.0 − 150.0) ÷ 150.0. Yet operating profit fell 28.0% and operating margin moved from 20.0 ÷ 150.0 = 13.3% to 14.4 ÷ 192.0 = 7.5%. The cohort view explains where to investigate without pretending to prove why.
合并口径显示收入增长 28.0%：（192.0 − 150.0）÷ 150.0；但营业利润下降 28.0%，营业利润率从 20.0 ÷ 150.0 = 13.3% 降至 14.4 ÷ 192.0 = 7.5%。站点批次视角能够指出应该去哪里调查，却不能假装已经证明原因。
| Profit location | FY2025 revenue / profit | FY2026 revenue / profit | FY2026 margin |
|---|---|---|---|
| Eight mature labs | 150.0 / 30.0 | 162.0 / 32.4 | 20.0% |
| Four new sites | — | 30.0 / −6.0 | −20.0% |
| Unallocated headquarters | — / −10.0 | — / −12.0 | Not meaningful |
| Consolidated | 150.0 / 20.0 | 192.0 / 14.4 | 7.5% |
| 利润位置 | FY2025 收入／利润 | FY2026 收入／利润 | FY2026 利润率 |
|---|---|---|---|
| 八家成熟实验室 | 150.0／30.0 | 162.0／32.4 | 20.0% |
| 四家新站点 | — | 30.0／−6.0 | −20.0% |
| 未分摊总部 | —／−10.0 | —／−12.0 | 无意义 |
| 合并公司 | 150.0／20.0 | 192.0／14.4 | 7.5% |
Mature-lab revenue grew 8.0% and its 20.0% margin held. New sites generated revenue but lost 6.0, while headquarters cost rose 2.0. Judgment: the mature engine appears stable and expansion depressed current profit. Missing evidence: test volumes, reimbursement mix, labor utilization, launch dates, and the path to site break-even. Never call new-site losses temporary merely because management calls them investments.
成熟实验室收入增长 8.0%，20.0% 的利润率保持不变；新站点已经产生收入，却亏损 6.0，总部费用也增加 2.0。判断是：成熟盈利引擎看起来稳定，扩张压低了当期利润。但检验量、支付方组合、人员利用率、开业日期和站点盈亏平衡路径仍然缺失。不能仅因管理层把新站点称为投资，就断言亏损一定是暂时的。
Examination room 2: measure the capital load检查室二：衡量资本负荷
Laboratory growth needs analyzers, fit-outs, information systems, and working space. CedarArc’s net property and equipment bridge is opening 80.0 + capital expenditure 45.0 − depreciation 18.0 − disposals 2.0 = closing 105.0. The fictional capital note assigns 32.0 of FY2026 capex to new sites and 13.0 to mature labs. Capex intensity is 45.0 ÷ 192.0 = 23.4%; depreciation intensity is 18.0 ÷ 192.0 = 9.4%. Their gap shows a build phase, not its return.
实验室增长需要分析设备、场地装修、信息系统与工作空间。CedarArc 的固定资产净额桥接为：期初 80.0 + 资本开支 45.0 − 折旧 18.0 − 处置 2.0 = 期末 105.0。虚构资本附注把 FY2026 资本开支中的 32.0 分配给新站点，13.0 分配给成熟实验室。资本开支强度为 45.0 ÷ 192.0 = 23.4%，折旧强度为 18.0 ÷ 192.0 = 9.4%；两者差距显示公司处于建设期，却不能说明建设回报。
Combining 13.0 of mature-lab spending with 32.0 of expansion prevents a clean view of maintenance needs and cohort economics. “Growth capex” is a management or analyst classification, not an automatic accounting fact.
集团总数掩盖了什么把成熟实验室的 13.0 支出与扩张的 32.0 合并，会遮蔽维持现有能力所需资金和新批次经济性。“增长性资本开支”是管理层或分析者分类，并非天然存在的会计事实。
Track each opening cohort until revenue, site contribution, utilization, and cumulative capital stabilize. A same-year return ratio would punish unfinished sites and can misstate the economics in either direction.
后续测量按开业批次持续跟踪收入、站点贡献、利用率和累计资本，直到趋于稳定。对尚未建成或仍在爬坡的站点计算当年回报率，会过早惩罚扩张，也可能向任一方向扭曲经济性。
Examination room 3: test the collection circulation检查室三：检查回款循环
Operating cash flow rose from 25.0 to 38.0, but one aggregate cash total cannot clear every subsystem. Trade receivables were 20.0 at the start of FY2025, 24.0 at its end, and 40.0 at FY2026 year-end. Using revenue as a proxy for credit sales, FY2025 days sales outstanding is ((20.0 + 24.0) ÷ 2) ÷ 150.0 × 365 = 53.5 days. FY2026 DSO is ((24.0 + 40.0) ÷ 2) ÷ 192.0 × 365 = 60.8 days, an increase of 7.3 days.
经营现金流从 25.0 升至 38.0，但一个合计现金数字不能替每个子系统解除疑点。贸易应收款在 FY2025 期初为 20.0、期末为 24.0，FY2026 期末升至 40.0。若以收入近似赊销额，FY2025 应收天数为［（20.0 + 24.0）÷ 2］÷ 150.0 × 365 = 53.5 天；FY2026 为［（24.0 + 40.0）÷ 2］÷ 192.0 × 365 = 60.8 天，增加 7.3 天。
The DSO calculation assumes total revenue approximates credit sales and two-point averages represent the year. Insurer, hospital, and patient terms may differ. The increase is an observation; slower payer processing, mix change, disputed claims, acquired balances, or weaker collection are rival explanations. Aging, allowances, write-offs, and later collections decide among them.
先写假设，再下判断该应收天数计算假设总收入能够近似赊销额，并假设期初期末两点平均能够代表全年；保险机构、医院和患者的付款条件可能不同。天数上升是观察结果，支付方处理变慢、收入组合变化、争议索赔、并入余额或回款恶化都是竞争性解释。应由账龄、损失准备、核销和期后收款来区分。
A strong group cash-flow line can coexist with a weak collection channel if payables, accrued compensation, taxes, or other timing items release cash. Reconcile the full operating-cash bridge; do not use 38.0 as a blanket rebuttal to the receivables signal.
若应付款、应计薪酬、税项或其他时点项目释放现金，集团经营现金流看起来强劲，也可能同时存在回款渠道恶化。必须核对完整经营现金流桥接，不能用 38.0 这个总数笼统否定应收款信号。
Examination room 4: separate cash on hand from cash at liberty检查室四：区分账上现金与可自由调度现金
Operating cash flow 38.0 minus cash capex 45.0 equals negative 7.0. Call this “cash after capex,” not standardized free cash flow; financing and some lease-related cash may be outside it. Of closing cash 30.0, 6.0 is restricted, leaving 24.0 unrestricted. If an analyst assumes 12.0 must remain for operations, the estimated discretionary buffer is 12.0: 30.0 − 6.0 − 12.0. That minimum is an assumption, not a reported reserve.
FY2026 经营现金流 38.0 减现金资本开支 45.0，得到 −7.0。应把它称为“资本开支后现金”，而不是标准化自由现金流；该数字尚未涵盖融资，并可能因会计框架与政策而遗漏部分租赁相关现金。CedarArc 期末现金 30.0，其中 6.0 受限，因此非受限现金为 24.0。若分析者假设工资与运营必须保留 12.0，则估计可自由调度缓冲只有 12.0：30.0 − 6.0 − 12.0。运营最低现金是假设，不是公司报告的储备。
| Funding claim at FY2026 close | Amount | Next evidence |
|---|---|---|
| Bank debt | 70.0 | Rates, covenants, security, 15.0 due within 12 months |
| Lease liabilities | 55.0 | Maturity table, options, variable payments, 10.0 due within 12 months |
| Unrestricted cash | 24.0 | Entity location, transfer limits, required balances |
| Estimated discretionary buffer | 12.0 | Sensitivity to the assumed 12.0 operating minimum |
| FY2026 期末融资请求权 | 金额 | 下一项证据 |
|---|---|---|
| 银行债务 | 70.0 | 利率、契约、担保，以及十二个月内到期 15.0 |
| 租赁负债 | 55.0 | 到期表、续租选择权、可变付款，以及十二个月内到期 10.0 |
| 非受限现金 | 24.0 | 所在法律实体、转移限制、必须维持的余额 |
| 估计可自由调度缓冲 | 12.0 | 对运营最低现金 12.0 假设进行敏感性测试 |
Debt and lease liabilities are not interchangeable, but both compete for future cash. Analyze contractual timing, security, covenants, renewal dependence, and refinancing access before compressing them into one leverage ratio.
债务与租赁负债并非可以互换的项目，但二者都会争夺未来现金。在把它们压缩成一个杠杆率之前，应分别分析合同到期时点、担保、契约、续租依赖与再融资渠道。
Examination room 5: scan segment and headquarters allocation检查室五：扫描分部与总部资源配置
Segment reporting reflects how management reviews activities and allocates resources, but the reported measure can differ from consolidated accounting. CedarArc’s segment reconciliation sends 32.4 of mature-lab profit and negative 6.0 from new sites through 12.0 of headquarters cost to reach 14.4. The reconciliation is essential: ignoring headquarters overstates company economics; allocating all headquarters cost by revenue may unfairly burden mature labs or conceal services consumed by new sites.
分部报告反映管理层如何审视业务并配置资源，但所报告分部指标可能不同于合并会计口径。CedarArc 的分部调节把成熟实验室利润 32.4、新站点亏损 6.0 和总部费用 12.0 连接到合并营业利润 14.4。调节不可省略：忽略总部会高估公司经济性；单纯按收入分摊全部总部费用，又可能不公平地压低成熟实验室表现，或掩盖新站点实际消耗的共享服务。
| Resource decision | FY2026 fact | Triage question |
|---|---|---|
| Cash capex | 32.0 new sites; 13.0 mature labs | What capacity or reliability did each dollar buy? |
| Lease liabilities | 38.0 assigned to new sites; 17.0 mature labs | Which sites need renewals to remain viable? |
| Share-based compensation expense | 5.0 total; 4.0 in headquarters | Which talent and decisions does dilution fund? |
| Headquarters cost | 12.0, including the 4.0 above | Which costs are shared, scalable, or avoidable? |
| 资源决策 | FY2026 事实 | 分诊问题 |
|---|---|---|
| 现金资本开支 | 新站点 32.0；成熟实验室 13.0 | 每一美元买到了什么产能或可靠性？ |
| 租赁负债 | 新站点 38.0；成熟实验室 17.0 | 哪些站点必须续租才能维持经营？ |
| 股份薪酬费用 | 合计 5.0；其中总部 4.0 | 稀释支持了哪些人才与决策？ |
| 总部费用 | 12.0，其中包含上述 4.0 | 哪些成本共享、可扩展或可避免？ |
Corporate cost may lack revenue, yet legal, billing, compliance, IT, and capital-allocation functions enable the network. Test its trajectory and allocation logic; do not automatically add it back to invent a stand-alone margin.
不要把控制中心“调整掉”总部费用不直接产生收入，但法律、结算、合规、信息技术和资本配置职能支撑整个网络。应检验总部成本趋势及分摊逻辑，而不是自动加回，从而虚构一个独立利润率。
Build a company-wide evidence packet from the complete filing set从完整申报资料建立公司级证据包
Upload comparable primary statements, the equity statement, MD&A, segment reconciliation, and property, receivables, debt, lease, restricted-cash, compensation, and EPS notes. Ask InfiniSynapse Stock Explained to organize evidence by profit engine, capital load, cash usability, funding claim, allocation, and per-share outcome. Retain each figure’s period, unit, accounting label, segment scope, source page, and status as audited, management-defined, or analyst-calculated.
Use the output as an index, not authority. Recheck every material amount, sign, denominator, maturity, restriction, and segment definition against the uploaded original statements and notes. Reperform the reconciliation from segments to consolidated profit and from attributable income to basic and diluted EPS. If the filing does not support a cohort split, cash-transfer claim, or causal explanation, leave it missing instead of allowing AI to complete the story.
上传可比期间的主表、权益变动表、管理层讨论、分部调节表，以及固定资产、应收款、债务、租赁、受限现金、股份薪酬和每股收益附注。要求 InfiniSynapse“一眼看懂这只股票”按照盈利引擎、资本负荷、现金可用性、融资请求权、资源配置决策和每股结果整理证据。每个提取数字必须保留期间、单位、会计名称、分部范围、来源页码，并标记它是经审计披露、管理层定义还是分析者计算。
把工具输出当作索引，而不是权威结论。每个重要金额、正负号、分母、到期时间、使用限制和分部定义，都要回到上传的原始报表与附注核验；还要亲自复算分部到合并营业利润、归属净利润到基本及稀释每股收益的调节。若申报文件不支持站点批次拆分、现金转移判断或因果解释，就保留缺失状态，不能让 AI 自动补全故事。
Include comparable periods, reporting units, segment definitions, and the company-level question that needs triage.
请一并提供可比期间、报告单位、分部定义，以及需要分诊的公司级问题。
Open Stock Explained打开“一眼看懂这只股票”Questions raised by a company-wide financial checkup公司级财务体检后常见的问题
Growth may come from an early-stage cohort with low utilization or launch costs while mature operations remain profitable. Reconcile mature operations, new activities, and headquarters, then test pricing, volume, mix, labor, and opening dates instead of assigning one cause from totals.
收入增长时，公司营业利润为什么可能下降？增长可能来自利用率较低、仍承担启动成本的新批次，而成熟业务仍然盈利。应把成熟业务、新业务与总部调节到合并结果，再检验价格、数量、组合、人工和开业日期，不能仅凭总数指定单一原因。
Not automatically. They remain operating costs unless the applicable presentation says otherwise. Isolate the cohort to study ramp economics, but retain the consolidated result. Repeated openings can make “start-up” losses recurring.
新站点亏损是否应该视为一次性项目？不能自动如此处理。除非适用会计列报另有说明，它们仍属于经营成本。分析时可以拆出该批次理解爬坡经济性，但必须保留报告合并结果；如果公司持续开站，“启动亏损”可能反而是战略中的经常性特征。
No. The gap indicates asset building but cannot separate maintenance, replacement, inflation, capacity, or timing. Use the fixed-asset roll-forward, disclosed allocation, site capacity, and later cohort output. Treat maintenance-versus-growth labels as estimates unless supported.
资本开支减折旧能否衡量增长成本？不能。差额显示净资产建设，却无法干净区分维护、替换、价格上涨、产能增长和时点差。应结合固定资产滚动表、管理层分配、站点产能及后续批次产出；除非披露直接支持，否则维持性与增长性分类只是估计。
Only for a defined question. Both create future cash claims, but their security, renewal economics, covenants, and accounting differ. Show them separately, inspect maturities and cash-flow classification, then explain any combined measure.
租赁负债是否应该加到银行债务中？只有在问题定义清楚时才能合并。两者都会形成未来现金请求权，但担保、灵活性、续租经济性、契约和会计处理不同。应先分别展示债务与租赁，核对到期表和现金流分类，再解释任何合并义务指标。
No total cancels a subsystem signal. Payables, accruals, taxes, or other balances may offset receivables. Inspect the full bridge, aging, allowances, write-offs, and later collections before attributing slower DSO to mix or collection risk.
经营现金流增强，能否消除对应收回款放慢的担忧？单一总数不能抵消某个子系统信号。应付款、应计项目、税款时点或其他余额，可能在经营现金流中抵消应收款影响。应检查完整桥接、支付方账龄、备抵、核销和期后收款，再判断应收天数变慢是组合变化还是回款风险。
Expense reduces profit; issued and potential shares affect how profit is divided. Vesting, forfeitures, withholding, repurchases, and diluted-EPS rules break a simple expense-to-share link, so reconcile both notes.
股份薪酬已经计入费用，为什么还要检查稀释？两者回答不同问题。费用减少报告利润，已发行与潜在股份则影响利润如何分配到每股。归属、没收、代扣、回购与稀释每股收益规则，会打破费用与股数之间的简单联系，因此两份附注都要调节。
Primary references behind the checkup本次体检依据的一手资料
CedarArc, every site cohort, statement amount, allocation, maturity, restriction, and operating explanation in this checkup are fictional teaching inputs. The arithmetic is internally defined but simplified; actual issuers may apply different accounting frameworks, segment measures, cash-flow classifications, and share calculations.
A financial checkup does not establish intrinsic value, forecast returns, diagnose fraud, or determine suitability. Read the full filing, notes, audit information, comparative history, covenants, and subsequent events, and obtain qualified advice where the decision requires it.
CedarArc、所有站点批次、报表金额、资源分配、到期事项、现金限制与经营解释，全部是虚构教学输入。算术在案例内部有明确定义，但经过简化；真实发行人可能采用不同会计框架、分部指标、现金流分类和每股计算方法。
公司财务体检不能单独确定内在价值、预测回报、诊断欺诈或判断个人适配性。应阅读完整申报、附注、审计信息、可比历史、契约和期后事项，并在决策需要时寻求合格专业意见。